By 2050 older people at risk for cognitive decline and Alzheimer's (AD) are predicted to reach 13 million and health care costs are borne by individuals, their families, and society at large. Cholinergic dysfunction Is a main stay of AD and cholinesterase Inhibitor drug remain the mainstay for the management of mild to moderate AD. Our goal is to elucidate the earliest molecular and cellular events underlying the selective neuronal vulnerability ofthe cholinergic basal forebrain (CBF) memory connectome during the preclinical stage ofthe disease. Accomplishing this goal will be crucial for the development of novel disease modifying therapeutics for AD. In AD, the magnitude of cholinergic neuron and volume loss within the CBF subfields displays a rostrocaudal variation with the greatest cells loss in Its caudal subfield, which projects mainly to medial temporal cortex followed by its intermediate subfield, which projects to the lateral parietal lobule, and then to the rostral subfield, the least affected region, which innervates the frontal cortex. This suggests a circuit-based spatiotemporal course of CBF degeneration, which occurs in a caudal to rostral progression. CBF degeneration is not only manifested by specific post-translational modifications related to tau, but by a confluence of intracellular events related to endosomal-lysosomal (E-L) dysfunction and aberrant epigenetic events begin during preclinical AD. Data from the current grant revealed that select E-L gene products are upregulated in anterior cholinergic neurons along with their respective protein levels in MCI. We now report that neuronal E-L dysregulatlon progresses from the caudal to the rostral cholinergic subfields In MCI and In preclinical AD NCI. Accumulating data also implicate epigenetic factors in regulating lysosomal gene transcription and function In AD yet whether epigenetic changes effect E-L expression early in the disease remains unknown. We will apply site-specific tau, E-L and epigenetic antibodies and single cell array technology to the CBF subfields from preclinical AD and MCI cases. The subproject is well positioned to lay the groundwork for a wide range of potential Interventions that are truly distinct from approaches currently under investigation and may suggest novel biomarkers for the early diagnosis of dementia.

Public Health Relevance

Cognitive decline associated with AD represent a major public health problem. Disease prevention provides the best long-term strategy to reduce the human and economic toll of AD. This timely study of preclincial AD molecular and cellular pathobiology could provide new knowledge critical to the development of novel drug therapies for dementia as well as impact public health policy needed to Impact our aging population.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG014449-16
Application #
8619879
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
Kelly, Sarah C; He, Bin; Perez, Sylvia E et al. (2017) Locus coeruleus cellular and molecular pathology during the progression of Alzheimer's disease. Acta Neuropathol Commun 5:8
McKay, Erin; Counts, Scott E (2017) Multi-Infarct Dementia: A Historical Perspective. Dement Geriatr Cogn Dis Extra 7:160-171
Perez, Sylvia E; Nadeem, Muhammad; Malek-Ahmadi, Michael H et al. (2017) Frontal Cortex and Hippocampal ?-Secretase Activating Protein Levels in Prodromal Alzheimer Disease. Neurodegener Dis 17:235-241
Marquié, Marta; Normandin, Marc D; Meltzer, Avery C et al. (2017) Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol 81:117-128
Ikonomovic, Milos D; Mi, Zhiping; Abrahamson, Eric E (2017) Disordered APP metabolism and neurovasculature in trauma and aging: Combined risks for chronic neurodegenerative disorders. Ageing Res Rev 34:51-63
Krivinko, Josh M; Erickson, Susan L; Abrahamson, Eric E et al. (2017) Kalirin reduction rescues psychosis-associated behavioral deficits in APPswe/PSEN1dE9 transgenic mice. Neurobiol Aging 54:59-70
Sorrentino, Vincenzo; Romani, Mario; Mouchiroud, Laurent et al. (2017) Enhancing mitochondrial proteostasis reduces amyloid-? proteotoxicity. Nature 552:187-193
Mahady, Laura J; Perez, Sylvia E; Emerich, Dwaine F et al. (2017) Cholinergic profiles in the Goettingen miniature pig (Sus scrofa domesticus) brain. J Comp Neurol 525:553-573
Counts, Scott E; Mufson, Elliott J (2017) Regulator of Cell Cycle (RGCC) Expression During the Progression of Alzheimer's Disease. Cell Transplant 26:693-702
Powers, Brian E; Kelley, Christy M; Velazquez, Ramon et al. (2017) Maternal choline supplementation in a mouse model of Down syndrome: Effects on attention and nucleus basalis/substantia innominata neuron morphology in adult offspring. Neuroscience 340:501-514

Showing the most recent 10 out of 270 publications